List of Signant SmartSignals eCOA Customers
Blue Bell, 19422, PA,
United States
Since 2010, our global team of researchers has been studying Signant SmartSignals eCOA customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Signant SmartSignals eCOA for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Signant SmartSignals eCOA for Clinical Trial Management include: Pfizer, a United States based Life Sciences organisation with 81000 employees and revenues of $63.63 billion, Shionogi, a Japan based Life Sciences organisation with 4955 employees and revenues of $2.87 billion and many others.
Contact us if you need a completed and verified list of companies using Signant SmartSignals eCOA, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Signant SmartSignals eCOA customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Pfizer | Life Sciences | 81000 | $63.6B | United States | Signant Health | Signant SmartSignals eCOA | Clinical Trial Management | 2020 | n/a |
In 2020, Pfizer implemented Signant SmartSignals eCOA to support clinical trial data collection for its COVID-19 vaccine program, using the platform within the Clinical Trial Management category. The deployment focused on eCOA for vaccine studies, supporting reactogenicity diaries and patient reported outcome capture across multiple countries including the United States, covering approximately 40,000 participants.
The Signant SmartSignals eCOA implementation emphasized high-volume, time stamped patient data capture and configuration of reactogenicity diary workflows and PRO instruments to align with protocol schedules and safety monitoring needs. Configuration work included form scheduling, timestamping of entries, and data validation rules to ensure consistent patient reported outcome records for downstream analysis.
Operational coverage extended across multi country clinical sites and remote participant reporting, enabling centralized receipt of diary and PRO data for safety review and efficacy assessment. The implementation remained focused on clinical trial data collection and eCOA workflows without introducing new named integrations beyond the core eCOA platform.
Governance and rollout were executed on a compressed timeline, delivering a five week implementation and a rapid go live to meet urgent trial timelines. The outcome was high volume, time stamped patient reported data that enabled timely safety and efficacy analyses during the COVID-19 vaccine program.
|
 |
Shionogi | Life Sciences | 4955 | $2.9B | Japan | Signant Health | Signant SmartSignals eCOA | Clinical Trial Management | 2021 | n/a |
In 2021, Shionogi deployed Signant SmartSignals eCOA to manage clinical trial eCOA and patient-reported outcomes for a Phase II/III COVID-19 therapeutic trial, using the Clinical Trial Management application to centralize PRO capture across study sites. The initial deployment began in Japan with site activation completed within approximately 10 weeks, covering more than 90 sites and with subsequent expansion into South Korea and other countries.
Signant SmartSignals eCOA was configured to capture real-time symptom diaries and physiological inputs such as blood oxygenation and body temperature, delivering timestamped PRO records and instrumented compliance reminders. The implementation emphasized eCOA form configuration, scheduling and automated notifications to support frequent patient-reported symptom capture and at-home biometric monitoring.
Operational ownership spanned clinical operations and data management functions, with the application supporting enrollment workflows, remote monitoring of patient compliance, and centralized PRO data collection for analysis. The deployment included protocol-aligned eCOA configuration and site activation processes to ensure consistent data capture across regions.
Outcomes reported from the implementation included faster enrollment, improved patient compliance, and higher-quality patient-reported outcome data suitable for regulatory assessment, with Signant SmartSignals eCOA enabling near real-time visibility into symptom trajectories and biometric signals during the Phase II/III COVID-19 study.
|
Buyer Intent: Companies Evaluating Signant SmartSignals eCOA
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||